Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy
Authors:
- 6 March 2013
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 111 (6) , 946-953
Abstract
What's known on the subject? and What does the study add?: Transrectal ultrasound guided prostate biopsies (TRUSBx) are associated with a spectrum of complications, including most significantly infection, which affects up to 5% of patients. In the most severe cases, infection leads to sepsis, a life‐threatening complication. Escherichia coli is the primary responsible pathogen. Although antibiotic prophylaxis with fluoroquinolones is routinely used, there is evidence that the infection rate after TRUSBx is increasing, and this appears to be due to an increasing prevalence of ciprofloxacin‐resistant rectal flora. This is the largest prospective clinical trial to date analysing the rectal flora of men undergoing prostate biopsies. We determined the microbial and antibiotic sensitivity profiles from 849 patients. Ciprofloxacin‐resistant Gram‐negative organisms were identified in the rectal flora of 19.0% of men. Furthermore, fluoroquinolone use within 6 months preceding a TRUSBx and the presence of a prosthetic heart valve were significant predictors of ciprofloxacin resistance on rectal swab. Determining the prevalence of rectal fluoroquinolone resistance has important implications in evaluation of the suitability of prophylactic regimens. Antimicrobial profiles derived from rectal swabs pre‐biopsy may prove useful in guiding targeted antibiotic prophylaxis. Objectives: To establish the prevalence of ciprofloxacin‐resistant bacteria in patients undergoing transrectal ultrasound guided prostate biopsies ( TRUSBx ) and to determine whether this predicts subsequent infectious complications. To identify risk factors for harbouring ciprofloxacin‐resistant flora. Patients and Methods: Any patient undergoing a TRUSBx from 2009 to 2011 was eligible for enrolment in this prospective study. Pre‐biopsy rectal and urine cultures and post‐biopsy urine cultures were obtained and antimicrobial susceptibility was determined. Univariate and multivariate analyses were performed to identify independent patient risk factors associated with ciprofloxacin‐resistant rectal flora. Results: A total of 865 patients underwent TRUSBx , of whom 19.0% were found to have ciprofloxacin‐resistant G ram‐negative coliforms. E scherichia coli was the most prevalent G ram‐negative rectal isolate (80.9%) and accounted for 90.6% of ciprofloxacin resistance. Patient characteristics that conferred an increased risk of harbouring ciprofloxacin‐resistant organisms included a history of a heart valve replacement ( P < 0.05) and ciprofloxacin use in the past 3 months ( P < 0.05). Infectious complications were observed in 3.6% ( n = 31) of the patient population and 48% of these patients grew ciprofloxacin‐resistant organisms on the pre‐biopsy rectal swab ( P < 0.001). Conclusions: Antimicrobial resistance to ciprofloxacin in the rectal flora was common, particularly in patients with recent ciprofloxacin use and a heart valve replacement. Despite a significant correlation between those patients who developed infections and the detection of ciprofloxacin‐resistant organisms, only 9.0% ( n = 15) of the total group with ciprofloxacin resistance developed an infectious complication. Future studies will need to evaluate the cost effectiveness and clinical utility of a pre‐biopsy rectal culture in targeting antibiotic prophylaxis.Keywords
This publication has 18 references indexed in Scilit:
- Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized TrialEuropean Urology, 2012
- Targeted Antimicrobial Prophylaxis Using Rectal Swab Cultures in Men Undergoing Transrectal Ultrasound Guided Prostate Biopsy is Associated With Reduced Incidence of Postoperative Infectious Complications and Cost of CareJournal of Urology, 2012
- Prevalence and Significance of Fluoroquinolone Resistant Escherichia coli in Patients Undergoing Transrectal Ultrasound Guided Prostate Needle BiopsyJournal of Urology, 2011
- Adding amikacin to fluoroquinolone‐based antimicrobial prophylaxis reduces prostate biopsy infection ratesBJU International, 2010
- Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsyBJU International, 2010
- Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coliEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Prevalence and Risk Factors for Selection of Quinolone-Resistant Escherichia coli Strains in Fecal Flora of Patients Receiving Quinolone TherapyAntimicrobial Agents and Chemotherapy, 2009
- Best Practice Policy Statement on Urologic Surgery Antimicrobial ProphylaxisJournal of Urology, 2008
- Empirical Management of Urinary Tract Infections Complicating Transrectal Ultrasound Guided Prostate BiopsyJournal of Urology, 2003
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992